Citigroup
AVBP icon

Citigroup’s ArriVent BioPharma AVBP Stock Holding History

Citigroup’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$627K Sell
20,708
-20,557
-50% -$630K ﹤0.01% 3618
2026
Q2 		$1.43M Buy
41,265
+33,830
+455% +$998K ﹤0.01% 3179
2026
Q1 		$172K Sell
7,435
-658
-8% -$14.9K ﹤0.01% 4068
2025
Q4 		$163K Sell
8,093
-1,944
-19% -$40.5K ﹤0.01% 4089
2025
Q3 		$185K Sell
10,037
-11,530
-53% -$227K ﹤0.01% 4023
2025
Q2 		$470K Sell
21,567
-12,602
-37% -$262K ﹤0.01% 3665
2025
Q1 		$632K Buy
34,169
+48
+0.1% +$1.18K ﹤0.01% 3548
2024
Q4 		$909K Buy
34,121
+13,721
+67% +$394K ﹤0.01% 3431
2024
Q3 		$479K Buy
20,400
+18,237
+843% +$414K ﹤0.01% 3757
2024
Q2 		$40.1K Buy
2,163
+422
+24% +$7.53K ﹤0.01% 4713
2024
Q1 		$31.1K Buy
+1,741
New +$35.1K ﹤0.01% 4879

Other funds holding AVBP

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Arizona State Retirement System
Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Citigroup's AVBP Position: Q3 2026 in Review

Citigroup reduced its ArriVent BioPharma (AVBP) stake by 50% in Q3 2026, selling an estimated $630K and leaving 20,708 shares worth $627K. The position accounts for ﹤0.01% of the portfolio, ranked #3618.

Citigroup first reported a position in AVBP in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.43M in Q2 2026. 31 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Citigroup held 20,708 shares of ArriVent BioPharma worth $627K as of Q3 2026.
  • Citigroup sold 20,557 ArriVent BioPharma shares in Q3 2026, an estimated $630K.
  • ArriVent BioPharma made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3618 holding.
  • Citigroup first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 11 quarters since.
  • Citigroup's ArriVent BioPharma position peaked at $1.43M in Q2 2026.
  • 31 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.